Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11294518,flow rate,"The mobile phase consisted of 16% isopropanol in water containing 0.1% trifluoroacetic acid, set at a flow rate of 1.2 mL/min.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),[ml] / [min],1.2,3291,DB00443,Betamethasone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,7.2,3292,DB00443,Betamethasone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,5.8,3293,DB00443,Betamethasone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,5.6,3294,DB00443,Betamethasone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,7.9,3295,DB00443,Betamethasone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,73,3296,DB00443,Betamethasone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,74,3297,DB00443,Betamethasone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,90,3298,DB00443,Betamethasone
,15860658,terminal half-life,"The phosphate formulation profile had the appearance of a traditional Bateman function with a terminal half-life of 4 h, whereas the phosphate/acetate formulation produced a biexponential decline with a terminal half-life of 14 h.",Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15860658/),h,4,7971,DB00443,Betamethasone
,15860658,terminal half-life,"The phosphate formulation profile had the appearance of a traditional Bateman function with a terminal half-life of 4 h, whereas the phosphate/acetate formulation produced a biexponential decline with a terminal half-life of 14 h.",Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15860658/),h,14,7972,DB00443,Betamethasone
,11823756,half-life,The half-life of betamethasone in mothers with twin pregnancies was significantly shorter than that in mothers with singleton pregnancies (7.2 +/-2.4 versus 9.0 +/- 2.7 hours; P <.017).,Pharmacokinetics of betamethasone in twin and singleton pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823756/),h,7.2,10466,DB00443,Betamethasone
,11823756,half-life,The half-life of betamethasone in mothers with twin pregnancies was significantly shorter than that in mothers with singleton pregnancies (7.2 +/-2.4 versus 9.0 +/- 2.7 hours; P <.017).,Pharmacokinetics of betamethasone in twin and singleton pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823756/),h,9.0,10467,DB00443,Betamethasone
,11823756,Clearance,Clearance of betamethasone in the twin pregnancies appeared greater than in singleton pregnancies (8.4 +/- 6.4 versus 5.7+/- 3.1 L/h; P =.06) but did not reach statistical significance.,Pharmacokinetics of betamethasone in twin and singleton pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823756/),[l] / [h],8.4,10468,DB00443,Betamethasone
,11823756,Clearance,Clearance of betamethasone in the twin pregnancies appeared greater than in singleton pregnancies (8.4 +/- 6.4 versus 5.7+/- 3.1 L/h; P =.06) but did not reach statistical significance.,Pharmacokinetics of betamethasone in twin and singleton pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823756/),[l] / [h],5.7,10469,DB00443,Betamethasone
,8148226,maximum plasma concentrations,"Mean maximum plasma concentrations were 5.0 and 0.24 ng ml-1 and mean AUC values were 75.4 and 7.74 ng ml-1 h after oral and topical administrations, respectively.",Plasma concentrations of betamethasone after topical application of betamethasone 17-valerate: comparison with oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148226/),[ng] / [ml],5.0,17569,DB00443,Betamethasone
,8148226,maximum plasma concentrations,"Mean maximum plasma concentrations were 5.0 and 0.24 ng ml-1 and mean AUC values were 75.4 and 7.74 ng ml-1 h after oral and topical administrations, respectively.",Plasma concentrations of betamethasone after topical application of betamethasone 17-valerate: comparison with oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148226/),[ng] / [ml],0.24,17570,DB00443,Betamethasone
,8148226,AUC,"Mean maximum plasma concentrations were 5.0 and 0.24 ng ml-1 and mean AUC values were 75.4 and 7.74 ng ml-1 h after oral and topical administrations, respectively.",Plasma concentrations of betamethasone after topical application of betamethasone 17-valerate: comparison with oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148226/),[h·ng] / [ml],75.4,17571,DB00443,Betamethasone
,8148226,AUC,"Mean maximum plasma concentrations were 5.0 and 0.24 ng ml-1 and mean AUC values were 75.4 and 7.74 ng ml-1 h after oral and topical administrations, respectively.",Plasma concentrations of betamethasone after topical application of betamethasone 17-valerate: comparison with oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148226/),[h·ng] / [ml],7.74,17572,DB00443,Betamethasone
,8148226,plasma elimination half-life,"The mean plasma elimination half-life of betamethasone after the removal of topical betamethasone 17-valerate was 16.6 h which was twice that after oral administration, 8.1 h.",Plasma concentrations of betamethasone after topical application of betamethasone 17-valerate: comparison with oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148226/),h,16.6,17573,DB00443,Betamethasone
,8148226,plasma elimination half-life,"The mean plasma elimination half-life of betamethasone after the removal of topical betamethasone 17-valerate was 16.6 h which was twice that after oral administration, 8.1 h.",Plasma concentrations of betamethasone after topical application of betamethasone 17-valerate: comparison with oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148226/),h,8.1,17574,DB00443,Betamethasone
,6662178,plasma clearance,"The plasma clearance of betamethasone phosphate (mean = 980 ml/min) and its apparent distribution volume (mean = 5.61) were both higher than previously found for nonpregnant subjects, but its half-life (mean = 4.6 min) was unchanged.",Disposition of betamethasone in parturient women after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662178/),[ml] / [min],980,22296,DB00443,Betamethasone
,6662178,apparent distribution volume,"The plasma clearance of betamethasone phosphate (mean = 980 ml/min) and its apparent distribution volume (mean = 5.61) were both higher than previously found for nonpregnant subjects, but its half-life (mean = 4.6 min) was unchanged.",Disposition of betamethasone in parturient women after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662178/),,5.61,22297,DB00443,Betamethasone
,6662178,half-life,"The plasma clearance of betamethasone phosphate (mean = 980 ml/min) and its apparent distribution volume (mean = 5.61) were both higher than previously found for nonpregnant subjects, but its half-life (mean = 4.6 min) was unchanged.",Disposition of betamethasone in parturient women after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662178/),min,4.6,22298,DB00443,Betamethasone
,6662178,terminal half-life,"Plasma concentrations of betamethasone reached a peak 5-37 min after dosing with betamethasone phosphate, then declined biexponentially with a mean terminal half-life of 262 min.",Disposition of betamethasone in parturient women after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662178/),min,262,22299,DB00443,Betamethasone
,6662178,Plasma clearance,Plasma clearance in pregnant patients (mean = 287 ml/min) was higher than previously reported for nonpregnant subjects.,Disposition of betamethasone in parturient women after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662178/),[ml] / [min],287,22300,DB00443,Betamethasone
,3235500,Peak serum methylprednisone concentrations,Peak serum methylprednisone concentrations of ca. 250 ng/ml occurred within 5 min of methylprednisolone administration and the average area under the curve ratio (methylprednisolone/methylprednisone) was 9.3.,"Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235500/),[ng] / [ml],250,24265,DB00443,Betamethasone
,3235500,area under the curve ratio,Peak serum methylprednisone concentrations of ca. 250 ng/ml occurred within 5 min of methylprednisolone administration and the average area under the curve ratio (methylprednisolone/methylprednisone) was 9.3.,"Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235500/),,9.3,24266,DB00443,Betamethasone
,7875637,terminal half life,The terminal half life (85.7 +/- 20.8 min and 102.2 +/- 29.6 min for DXM; 117.6 +/- 19.8 min and 118.5 +/- 15.8 min for BTM) and the mean residence time (121.4 +/- 27.7 min and 146.1 +/- 41.3 min for DXM; 168.6 +/- 28.1 min and 172.2 +/- 20.6 min for BTM) were unchanged between the doses.,Comparative pharmacokinetics of two diastereoisomers dexamethasone and betamethasone in plasma and cerebrospinal fluid in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875637/),min,85.7,43399,DB00443,Betamethasone
,7875637,terminal half life,The terminal half life (85.7 +/- 20.8 min and 102.2 +/- 29.6 min for DXM; 117.6 +/- 19.8 min and 118.5 +/- 15.8 min for BTM) and the mean residence time (121.4 +/- 27.7 min and 146.1 +/- 41.3 min for DXM; 168.6 +/- 28.1 min and 172.2 +/- 20.6 min for BTM) were unchanged between the doses.,Comparative pharmacokinetics of two diastereoisomers dexamethasone and betamethasone in plasma and cerebrospinal fluid in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875637/),min,102.2,43400,DB00443,Betamethasone
,7875637,terminal half life,The terminal half life (85.7 +/- 20.8 min and 102.2 +/- 29.6 min for DXM; 117.6 +/- 19.8 min and 118.5 +/- 15.8 min for BTM) and the mean residence time (121.4 +/- 27.7 min and 146.1 +/- 41.3 min for DXM; 168.6 +/- 28.1 min and 172.2 +/- 20.6 min for BTM) were unchanged between the doses.,Comparative pharmacokinetics of two diastereoisomers dexamethasone and betamethasone in plasma and cerebrospinal fluid in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875637/),min,117.6,43401,DB00443,Betamethasone
,7875637,terminal half life,The terminal half life (85.7 +/- 20.8 min and 102.2 +/- 29.6 min for DXM; 117.6 +/- 19.8 min and 118.5 +/- 15.8 min for BTM) and the mean residence time (121.4 +/- 27.7 min and 146.1 +/- 41.3 min for DXM; 168.6 +/- 28.1 min and 172.2 +/- 20.6 min for BTM) were unchanged between the doses.,Comparative pharmacokinetics of two diastereoisomers dexamethasone and betamethasone in plasma and cerebrospinal fluid in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875637/),min,118.5,43402,DB00443,Betamethasone
,7875637,mean residence time,The terminal half life (85.7 +/- 20.8 min and 102.2 +/- 29.6 min for DXM; 117.6 +/- 19.8 min and 118.5 +/- 15.8 min for BTM) and the mean residence time (121.4 +/- 27.7 min and 146.1 +/- 41.3 min for DXM; 168.6 +/- 28.1 min and 172.2 +/- 20.6 min for BTM) were unchanged between the doses.,Comparative pharmacokinetics of two diastereoisomers dexamethasone and betamethasone in plasma and cerebrospinal fluid in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875637/),min,121.4,43403,DB00443,Betamethasone
,7875637,mean residence time,The terminal half life (85.7 +/- 20.8 min and 102.2 +/- 29.6 min for DXM; 117.6 +/- 19.8 min and 118.5 +/- 15.8 min for BTM) and the mean residence time (121.4 +/- 27.7 min and 146.1 +/- 41.3 min for DXM; 168.6 +/- 28.1 min and 172.2 +/- 20.6 min for BTM) were unchanged between the doses.,Comparative pharmacokinetics of two diastereoisomers dexamethasone and betamethasone in plasma and cerebrospinal fluid in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875637/),min,146.1,43404,DB00443,Betamethasone
,7875637,mean residence time,The terminal half life (85.7 +/- 20.8 min and 102.2 +/- 29.6 min for DXM; 117.6 +/- 19.8 min and 118.5 +/- 15.8 min for BTM) and the mean residence time (121.4 +/- 27.7 min and 146.1 +/- 41.3 min for DXM; 168.6 +/- 28.1 min and 172.2 +/- 20.6 min for BTM) were unchanged between the doses.,Comparative pharmacokinetics of two diastereoisomers dexamethasone and betamethasone in plasma and cerebrospinal fluid in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875637/),min,168.6,43405,DB00443,Betamethasone
,7875637,mean residence time,The terminal half life (85.7 +/- 20.8 min and 102.2 +/- 29.6 min for DXM; 117.6 +/- 19.8 min and 118.5 +/- 15.8 min for BTM) and the mean residence time (121.4 +/- 27.7 min and 146.1 +/- 41.3 min for DXM; 168.6 +/- 28.1 min and 172.2 +/- 20.6 min for BTM) were unchanged between the doses.,Comparative pharmacokinetics of two diastereoisomers dexamethasone and betamethasone in plasma and cerebrospinal fluid in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875637/),min,172.2,43406,DB00443,Betamethasone
,31808984,terminal half-life,"Intramuscular or oral betamethasone has a terminal half-life of 11 hours, about twice as long as the 5.5 hours for oral and intramuscular dexamethasone.",Pharmacokinetics and Pharmacodynamics of Intramuscular and Oral Betamethasone and Dexamethasone in Reproductive Age Women in India. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31808984/),h,11,45039,DB00443,Betamethasone
,31808984,terminal half-life,"Intramuscular or oral betamethasone has a terminal half-life of 11 hours, about twice as long as the 5.5 hours for oral and intramuscular dexamethasone.",Pharmacokinetics and Pharmacodynamics of Intramuscular and Oral Betamethasone and Dexamethasone in Reproductive Age Women in India. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31808984/),h,5.5,45040,DB00443,Betamethasone
,19383806,time to reach a clinical,The time to reach a clinically significant plasma concentration of cortisol (>200 nmol/l) was within 20 min and a mean peak of 431 (s.d. 126) nmol/l was obtained within 50 min after administration of the 20 mg tablet.,Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19383806/),min,20,58042,DB00443,Betamethasone
,19383806,peak,The time to reach a clinically significant plasma concentration of cortisol (>200 nmol/l) was within 20 min and a mean peak of 431 (s.d. 126) nmol/l was obtained within 50 min after administration of the 20 mg tablet.,Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19383806/),[nM] / [l],431,58043,DB00443,Betamethasone
,19383806,time to reach 200 nmol/l,"In the fed state the time to reach 200 nmol/l was delayed by 28 and 9 min based on LC-MS/MS and immunoassay, respectively.",Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19383806/),min,28,58044,DB00443,Betamethasone
,19383806,time to reach 200 nmol/l,"In the fed state the time to reach 200 nmol/l was delayed by 28 and 9 min based on LC-MS/MS and immunoassay, respectively.",Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19383806/),min,9,58045,DB00443,Betamethasone
,16446602,clearance,"Amikacin clearance was 0.46 (range, 0.09-2.33) mL/kg/min and distribution volume was 0.54 (range, 0.17-2.31) L/kg.",Dopamine is not an independent risk factor for reduced amikacin clearance in extremely low-birth-weight infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446602/),[ml] / [kg·min],0.46,61445,DB00443,Betamethasone
,16446602,distribution volume,"Amikacin clearance was 0.46 (range, 0.09-2.33) mL/kg/min and distribution volume was 0.54 (range, 0.17-2.31) L/kg.",Dopamine is not an independent risk factor for reduced amikacin clearance in extremely low-birth-weight infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446602/),[l] / [kg],0.54,61446,DB00443,Betamethasone
,28117560,Maximum measured plasma betamethasone concentrations,Maximum measured plasma betamethasone concentrations were 3.97 ± 0.23 ng/mL at 1.45 ± 0.20 h.,"Pharmacokinetics of betamethasone in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28117560/),[ng] / [ml],3.97,64275,DB00443,Betamethasone
,28117560,plasma elimination half-life,The plasma elimination half-life was 7.48 ± 0.39 h.,"Pharmacokinetics of betamethasone in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28117560/),h,7.48,64276,DB00443,Betamethasone
,7104209,half-life,There was a simultaneous increase in the concentration of betamethasone-21-valerate which peaked within 2 days and was followed by a slow degradation (half-life 8 days) to betamethasone free alcohol.,The stability and blanching efficacy of betamethasone-17-valerate in emulsifying ointment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104209/),d,8,79866,DB00443,Betamethasone
,7062220,Elimination half-life,"Elimination half-life was inversely related to gestational age, and ranged from 22.5 to 109 hours.",Pharmacokinetics and tissue distribution of metronidazole in the new born infant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062220/),h,22.5 to 109,85592,DB00443,Betamethasone
,16946223,t(1/2),Both betamethasone preparations produced highest maternal concentrations after 15 min followed by an exponential decline with a t(1/2) of about 3 hours.,Kinetics of betamethasone and fetal cardiovascular adverse effects in pregnant sheep after different doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16946223/),h,3,89605,DB00443,Betamethasone
,8549229,half-life,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),h,1.150,98700,DB00443,Betamethasone
,8549229,excretion constant,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ke] / [h],0.686,98701,DB00443,Betamethasone
,8549229,volume of distribution,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [kg],607,98702,DB00443,Betamethasone
,8549229,clearance rate,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [h·kg],374,98703,DB00443,Betamethasone
,14710109,peak fetal betamethasone concentrations,Fetal injection caused higher peak fetal betamethasone concentrations (341.2+/-23.7 nmol/L) than maternal injection (37.6+/-3.7 nmol/L; P<.001) and greater cumulative betamethasone exposure.,Pharmacokinetics of betamethasone after maternal or fetal intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14710109/),[nM] / [l],341.2,106101,DB00443,Betamethasone
,14710109,peak fetal betamethasone concentrations,Fetal injection caused higher peak fetal betamethasone concentrations (341.2+/-23.7 nmol/L) than maternal injection (37.6+/-3.7 nmol/L; P<.001) and greater cumulative betamethasone exposure.,Pharmacokinetics of betamethasone after maternal or fetal intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14710109/),[nM] / [l],37.6,106102,DB00443,Betamethasone
,14710109,half-life,The half-life of betamethasone in the fetal circulation was shorter after fetal injection (1.1+/-0.3 hours) than after maternal injection (8.5+/-2.0 hours; P=.006).,Pharmacokinetics of betamethasone after maternal or fetal intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14710109/),h,1.1,106103,DB00443,Betamethasone
,14710109,half-life,The half-life of betamethasone in the fetal circulation was shorter after fetal injection (1.1+/-0.3 hours) than after maternal injection (8.5+/-2.0 hours; P=.006).,Pharmacokinetics of betamethasone after maternal or fetal intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14710109/),h,8.5,106104,DB00443,Betamethasone
,18664204,flow rate,"The analyte was isocratically eluted on a Venusil XBP C8 column (200 mm x 3.9 mm ID, 5 microm) with methanol-water mol x L(-1) ammonium formate) (80:20) at a flow rate of 0.4 mL x min(-1), and detected (containing 5 mmol x L(-1) ammonium formate) (80:20) at a flow rate of 0.4 mL x min(-1), and detected with a triple quad LC-MS/MS using ESI with positive ionization.",Determination of betamethasone in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18664204/),[ml] / [min],0.4,111928,DB00443,Betamethasone
,18664204,m/,Ions monitored in the multiple reaction monitoring (MRM) mode were m/z 393.3-->355.2 for betamethasone and m/z 361.3-->343.2 for prednisolone (IS).,Determination of betamethasone in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18664204/),,393.3,111929,DB00443,Betamethasone
,18664204,m/z,Ions monitored in the multiple reaction monitoring (MRM) mode were m/z 393.3-->355.2 for betamethasone and m/z 361.3-->343.2 for prednisolone (IS).,Determination of betamethasone in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18664204/),,361.3,111930,DB00443,Betamethasone
,18664204,m/z,Ions monitored in the multiple reaction monitoring (MRM) mode were m/z 393.3-->355.2 for betamethasone and m/z 361.3-->343.2 for prednisolone (IS).,Determination of betamethasone in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18664204/),,343.2,111931,DB00443,Betamethasone
,18664204,recovery,The average recovery is 88.24% and the low limit of quantitation (LLOQ) was 0.5 ng x mL(-1).,Determination of betamethasone in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18664204/),%,88.24,111932,DB00443,Betamethasone
,33389521,clearance,"Typical values for dexamethasone were clearance ([Formula: see text] of 9.29 L/h, steady-state volume ([Formula: see text] of 56.4 L, IM absorption constant [Formula: see text] of 0.460 1/h and oral absorption constant ([Formula: see text] of 0.936 1/h.",Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33389521/),[l] / [h],9.29,118035,DB00443,Betamethasone
,33389521,steady-state volume,"Typical values for dexamethasone were clearance ([Formula: see text] of 9.29 L/h, steady-state volume ([Formula: see text] of 56.4 L, IM absorption constant [Formula: see text] of 0.460 1/h and oral absorption constant ([Formula: see text] of 0.936 1/h.",Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33389521/),l,56.4,118036,DB00443,Betamethasone
,33389521,absorption constant,"Typical values for dexamethasone were clearance ([Formula: see text] of 9.29 L/h, steady-state volume ([Formula: see text] of 56.4 L, IM absorption constant [Formula: see text] of 0.460 1/h and oral absorption constant ([Formula: see text] of 0.936 1/h.",Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33389521/),[1] / [h],0.460,118037,DB00443,Betamethasone
,33389521,oral absorption constant,"Typical values for dexamethasone were clearance ([Formula: see text] of 9.29 L/h, steady-state volume ([Formula: see text] of 56.4 L, IM absorption constant [Formula: see text] of 0.460 1/h and oral absorption constant ([Formula: see text] of 0.936 1/h.",Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33389521/),[1] / [h],0.936,118038,DB00443,Betamethasone
,33389521,CL/FIM,"Betamethasone parameters were CL/FIM of 5.95 L/h, [Formula: see text] of 72.4 L, [Formula: see text] of 0.971 1/h, and [Formula: see text] of 1.21 1/h.",Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33389521/),[l] / [h],5.95,118039,DB00443,Betamethasone
,33389521,F,The PO to IM F values were close to 1.0 for both drugs.,Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33389521/),,1.0,118040,DB00443,Betamethasone
,33389521,terminal half-lives,"The terminal half-lives averaged about 7.5 h for DEX, 17 h for BET, and 78 h for BET from BET-PA with the latter reflecting very slow release of BET from the acetate ester.",Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33389521/),h,7.5,118041,DB00443,Betamethasone
,33389521,terminal half-lives,"The terminal half-lives averaged about 7.5 h for DEX, 17 h for BET, and 78 h for BET from BET-PA with the latter reflecting very slow release of BET from the acetate ester.",Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33389521/),h,17,118042,DB00443,Betamethasone
,33389521,terminal half-lives,"The terminal half-lives averaged about 7.5 h for DEX, 17 h for BET, and 78 h for BET from BET-PA with the latter reflecting very slow release of BET from the acetate ester.",Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33389521/),h,78,118043,DB00443,Betamethasone
,16390350,volume of distribution (V),The population parameter estimate for volume of distribution (V) was 40.2 l per 70 kg.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·kg],40.2,120128,DB00443,Betamethasone
,16390350,Clearance (CL),Clearance (CL) increased from 0.486 l h(-1) per 70 kg at 24 weeks PCA to 0.940 l h(-1) per 70 kg by 30 weeks PCA.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·h·kg],0.486,120129,DB00443,Betamethasone
,16390350,Clearance (CL),Clearance (CL) increased from 0.486 l h(-1) per 70 kg at 24 weeks PCA to 0.940 l h(-1) per 70 kg by 30 weeks PCA.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·h·kg],0.940,120130,DB00443,Betamethasone
,25919644,retention times,The retention times were 0.75 min for finasteride and 0.85 min for IS.,Finasteride Quantification in Human Plasma by High-Performance Liquid Chromatography Coupled to Electrospray Ionization Tandem Mass Spectrometry. Application to a Comparative Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25919644/),min,0.75,120607,DB00443,Betamethasone
,25919644,retention times,The retention times were 0.75 min for finasteride and 0.85 min for IS.,Finasteride Quantification in Human Plasma by High-Performance Liquid Chromatography Coupled to Electrospray Ionization Tandem Mass Spectrometry. Application to a Comparative Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25919644/),min,0.85,120608,DB00443,Betamethasone
,25847081,Tmax,BTM in plasma had greater Tmax (Tmax 0.8 h) vs. urine (Tmax 7.1 h).,Pharmacokinetics of intra-articular betamethasone sodium phosphate and betamethasone acetate and endogenous hydrocortisone suppression in exercising horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25847081/),h,0.8,124835,DB00443,Betamethasone
,25847081,Tmax,BTM in plasma had greater Tmax (Tmax 0.8 h) vs. urine (Tmax 7.1 h).,Pharmacokinetics of intra-articular betamethasone sodium phosphate and betamethasone acetate and endogenous hydrocortisone suppression in exercising horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25847081/),h,7.1,124836,DB00443,Betamethasone
exceeded,125164,Production rate (PR),"Production rate (PR) of testosterone exceeded 417 mug/24 h (1 SD above the mean reported for normal women), in nineteen of the twenty-five patients.",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],417,150467,DB00443,Betamethasone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],509,150468,DB00443,Betamethasone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],356,150469,DB00443,Betamethasone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],612,150470,DB00443,Betamethasone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],345,150471,DB00443,Betamethasone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],528,150472,DB00443,Betamethasone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],148,150473,DB00443,Betamethasone
,31744668,flow rate,"Using testosterone as internal standard, the plasma samples were prepared by precipitation with acetonitrile and separated using an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) with a mobile phase composed of acetonitrile and 0.1 % (v/v) formic acid aqueous solution by gradient elution at a flow rate of 0.3 mL/min.",Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31744668/),[ml] / [min],0.3,155222,DB00443,Betamethasone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.8,161897,DB00443,Betamethasone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.4,161898,DB00443,Betamethasone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.3,161899,DB00443,Betamethasone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,2.1,161900,DB00443,Betamethasone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,2.5,161901,DB00443,Betamethasone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,3.5,161902,DB00443,Betamethasone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],139,161903,DB00443,Betamethasone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],141,161904,DB00443,Betamethasone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],722,161905,DB00443,Betamethasone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],114,161906,DB00443,Betamethasone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],75,161907,DB00443,Betamethasone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],153,161908,DB00443,Betamethasone
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.3,161909,DB00443,Betamethasone
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.4,161910,DB00443,Betamethasone
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.2,161911,DB00443,Betamethasone
,21899210,time to maximum concentration,"When compared to BOH, B17P exhibited a longer time to maximum concentration (15.0 +/- 9.0 h vs. 2.8 +/- 1.7 h), a lower Cmax (0.6 +/- 0.2 ng/mL vs. 14.5 +/- 3.7 ng/mL), and a much longer half-life (80.8 +/- 22.7 h vs. 9.6 +/- 3.6 h).",Pharmacokinetics of betamethasone and betamethasone 17-monopropionate in Chinese healthy volunteers after intramuscular injection of betamethasone phosphate/betamethasone dipropionate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899210/),h,15.0,162576,DB00443,Betamethasone
,21899210,time to maximum concentration,"When compared to BOH, B17P exhibited a longer time to maximum concentration (15.0 +/- 9.0 h vs. 2.8 +/- 1.7 h), a lower Cmax (0.6 +/- 0.2 ng/mL vs. 14.5 +/- 3.7 ng/mL), and a much longer half-life (80.8 +/- 22.7 h vs. 9.6 +/- 3.6 h).",Pharmacokinetics of betamethasone and betamethasone 17-monopropionate in Chinese healthy volunteers after intramuscular injection of betamethasone phosphate/betamethasone dipropionate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899210/),h,2.8,162577,DB00443,Betamethasone
,21899210,Cmax,"When compared to BOH, B17P exhibited a longer time to maximum concentration (15.0 +/- 9.0 h vs. 2.8 +/- 1.7 h), a lower Cmax (0.6 +/- 0.2 ng/mL vs. 14.5 +/- 3.7 ng/mL), and a much longer half-life (80.8 +/- 22.7 h vs. 9.6 +/- 3.6 h).",Pharmacokinetics of betamethasone and betamethasone 17-monopropionate in Chinese healthy volunteers after intramuscular injection of betamethasone phosphate/betamethasone dipropionate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899210/),[ng] / [ml],0.6,162578,DB00443,Betamethasone
,21899210,Cmax,"When compared to BOH, B17P exhibited a longer time to maximum concentration (15.0 +/- 9.0 h vs. 2.8 +/- 1.7 h), a lower Cmax (0.6 +/- 0.2 ng/mL vs. 14.5 +/- 3.7 ng/mL), and a much longer half-life (80.8 +/- 22.7 h vs. 9.6 +/- 3.6 h).",Pharmacokinetics of betamethasone and betamethasone 17-monopropionate in Chinese healthy volunteers after intramuscular injection of betamethasone phosphate/betamethasone dipropionate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899210/),[ng] / [ml],14.5,162579,DB00443,Betamethasone
,21899210,half-life,"When compared to BOH, B17P exhibited a longer time to maximum concentration (15.0 +/- 9.0 h vs. 2.8 +/- 1.7 h), a lower Cmax (0.6 +/- 0.2 ng/mL vs. 14.5 +/- 3.7 ng/mL), and a much longer half-life (80.8 +/- 22.7 h vs. 9.6 +/- 3.6 h).",Pharmacokinetics of betamethasone and betamethasone 17-monopropionate in Chinese healthy volunteers after intramuscular injection of betamethasone phosphate/betamethasone dipropionate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899210/),h,80.8,162580,DB00443,Betamethasone
,21899210,half-life,"When compared to BOH, B17P exhibited a longer time to maximum concentration (15.0 +/- 9.0 h vs. 2.8 +/- 1.7 h), a lower Cmax (0.6 +/- 0.2 ng/mL vs. 14.5 +/- 3.7 ng/mL), and a much longer half-life (80.8 +/- 22.7 h vs. 9.6 +/- 3.6 h).",Pharmacokinetics of betamethasone and betamethasone 17-monopropionate in Chinese healthy volunteers after intramuscular injection of betamethasone phosphate/betamethasone dipropionate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899210/),h,9.6,162581,DB00443,Betamethasone
,14711849,Serum half life,Serum half life was 277 (143) minutes in the preterm infants and 172 (59) minutes in the term infants (p < 0.05).,Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14711849/),min,277,168689,DB00443,Betamethasone
,14711849,Serum half life,Serum half life was 277 (143) minutes in the preterm infants and 172 (59) minutes in the term infants (p < 0.05).,Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14711849/),min,172,168690,DB00443,Betamethasone
,14711849,Clearance,Clearance was 0.116 (0.08) litre/kg/h in the preterm infants and 0.170 (0.06) litre/kg/h in the term infants (p < 0.05).,Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14711849/),[l] / [h·kg],0.116,168691,DB00443,Betamethasone
,14711849,Clearance,Clearance was 0.116 (0.08) litre/kg/h in the preterm infants and 0.170 (0.06) litre/kg/h in the term infants (p < 0.05).,Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14711849/),[l] / [h·kg],0.170,168692,DB00443,Betamethasone
,6330019,elimination half-life (T 1/2 beta),"No significant differences in the pharmacokinetics of cefotaxime were observed between the various groups, with elimination half-life (T 1/2 beta) of cefotaxime ranging from 4.04 +/- 1.52 to 4.56 +/- 1.31 h.",Pharmacokinetics of cefotaxime in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6330019/),h,4.04,173723,DB00443,Betamethasone
,6330019,elimination half-life (T 1/2 beta),"No significant differences in the pharmacokinetics of cefotaxime were observed between the various groups, with elimination half-life (T 1/2 beta) of cefotaxime ranging from 4.04 +/- 1.52 to 4.56 +/- 1.31 h.",Pharmacokinetics of cefotaxime in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6330019/),h,4.56,173724,DB00443,Betamethasone
,22913456,efflux rate per,The average BM efflux rate per minute was calculated to be 5.1 μg/min with values ranging from 9 μg/min to 2.9 μg/min.,The isolated perfused equine distal limb as an ex vivo model for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913456/),[μg] / [min],5.1,189173,DB00443,Betamethasone
,22913456,efflux rate per,The average BM efflux rate per minute was calculated to be 5.1 μg/min with values ranging from 9 μg/min to 2.9 μg/min.,The isolated perfused equine distal limb as an ex vivo model for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913456/),[μg] / [min],9,189174,DB00443,Betamethasone
,22913456,efflux rate per,The average BM efflux rate per minute was calculated to be 5.1 μg/min with values ranging from 9 μg/min to 2.9 μg/min.,The isolated perfused equine distal limb as an ex vivo model for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913456/),[μg] / [min],2.9,189175,DB00443,Betamethasone
>,23973630,extraction recovery,Matrix effect was assessed by post-column analyte infusion and the extraction recovery was >95.0% across four quality control levels for the analyte and IS.,Analysis of 21-hydroxy deflazacort in human plasma by UPLC-MS/MS: application to a bioequivalence study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23973630/),%,95.0,192885,DB00443,Betamethasone
,6662164,half-life,Betamethasone phosphate disappeared rapidly from plasma (mean half-life = 4.7 min) as betamethasone levels rose.,Pharmacokinetics of betamethasone in healthy adults after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662164/),min,4.7,201240,DB00443,Betamethasone
,6662164,half-life,The terminal slow disposition phase had a mean half-life of 6.5 h.,Pharmacokinetics of betamethasone in healthy adults after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662164/),h,6.5,201241,DB00443,Betamethasone
,18757252,flow rate,"Both compounds were extracted from human plasma with ether-cyclohexane (4:1, v/v) and were separated by HPLC on a Hanbon Lichrospher C(18) column with a mobile phase of methanol-water (85:15, v/v) at a flow rate of 0.7ml/min.",Determination of betamethasone and betamethasone 17-monopropionate in human plasma by liquid chromatography-positive/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757252/),[ml] / [min],0.7,230243,DB00443,Betamethasone
,18757252,plasma extraction recovery,"The mean plasma extraction recovery for BOH and B17P were in the ranges of 82.7-85.9% and 83.6-85.3%, respectively.",Determination of betamethasone and betamethasone 17-monopropionate in human plasma by liquid chromatography-positive/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757252/),%,82.7-85.9,230244,DB00443,Betamethasone
,18757252,plasma extraction recovery,"The mean plasma extraction recovery for BOH and B17P were in the ranges of 82.7-85.9% and 83.6-85.3%, respectively.",Determination of betamethasone and betamethasone 17-monopropionate in human plasma by liquid chromatography-positive/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757252/),%,83.6-85.3,230245,DB00443,Betamethasone
,25899007,tmax median,Co-administration of OBE001 and betamethasone was well tolerated and resulted in a tmax median delay of 1 h for OBE001 but not for betamethasone.,Pharmacokinetic interactions of OBE001 and betamethasone in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25899007/),h,1,239519,DB00443,Betamethasone
,21182429,K(i),"BMP had the highest K(i) value (8.4 × 10(-8) nmol/L), whereas DFB had the lowest (6.1 × 10(-11) nmol/L).",Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182429/),[nM] / [l],8.4 × 10(-8),253153,DB00443,Betamethasone
,21182429,K(i),"BMP had the highest K(i) value (8.4 × 10(-8) nmol/L), whereas DFB had the lowest (6.1 × 10(-11) nmol/L).",Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182429/),[nM] / [l],6.1 × 10(-11),253154,DB00443,Betamethasone
,21182429,GCRBA,The GCRBA of DFBA was intermediate to these 2 values (7.8 × 10(-10) nmol/L).,Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182429/),[nM] / [l],7.8 × 10(-10),253155,DB00443,Betamethasone
<,9619751,AUC,Five patients demonstrated extremely low AUC and Cmax (< 10 ng/ml) values on day 1.,Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619751/),[ng] / [ml],10,257240,DB00443,Betamethasone
<,9619751,Cmax,Five patients demonstrated extremely low AUC and Cmax (< 10 ng/ml) values on day 1.,Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619751/),[ng] / [ml],10,257241,DB00443,Betamethasone
,29128828,half-life,The half-life of betamethasone was 8.5days.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),d,8.5,259718,DB00443,Betamethasone
,29128828,elimination rate constant,The elimination rate constant was 2.49h-1; the mean clearance was 4.72L/d.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),1/[h],2.49,259719,DB00443,Betamethasone
,29128828,clearance,The elimination rate constant was 2.49h-1; the mean clearance was 4.72L/d.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),[l] / [d],4.72,259720,DB00443,Betamethasone
,22154197,AUC(0-t),Betamethasone phosphate appeared to be readily absorbed with a mean AUC(0-t) of 96.01 ng/h/mL and an AUC(0-∞) of 97.96 (23.38) ng/h/mL.,Pharmacokinetics of betamethasone after single-dose intramuscular administration of betamethasone phosphate and betamethasone acetate to healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154197/),[ng] / [h·ml],96.01,267927,DB00443,Betamethasone
,22154197,AUC(0-∞),Betamethasone phosphate appeared to be readily absorbed with a mean AUC(0-t) of 96.01 ng/h/mL and an AUC(0-∞) of 97.96 (23.38) ng/h/mL.,Pharmacokinetics of betamethasone after single-dose intramuscular administration of betamethasone phosphate and betamethasone acetate to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154197/),[ng] / [h·ml],97.96,267928,DB00443,Betamethasone
,22154197,t(½),Betamethasone peak plasma concentration reached a mean t(½) of 12.92 hours.,Pharmacokinetics of betamethasone after single-dose intramuscular administration of betamethasone phosphate and betamethasone acetate to healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154197/),h,12.92,267929,DB00443,Betamethasone
,29466046,percentage absorption,"RESULTS During the 24-hour experiment, mean ± SD percentage absorption without the presence of synthetic canine cerumen was 0.28 ± 0.09% for 3H-betamethasone acetate, 0.06 ± 0.06% for florfenicol, and 0.06 ± 0.02% for 14C-terbinafine hydrochloride.","Impact of synthetic canine cerumen on in vitro penetration of auricular skin of dogs by florfenicol, terbinafine, and betamethasone acetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466046/),%,0.28,272299,DB00443,Betamethasone
,29466046,percentage absorption,"RESULTS During the 24-hour experiment, mean ± SD percentage absorption without the presence of synthetic canine cerumen was 0.28 ± 0.09% for 3H-betamethasone acetate, 0.06 ± 0.06% for florfenicol, and 0.06 ± 0.02% for 14C-terbinafine hydrochloride.","Impact of synthetic canine cerumen on in vitro penetration of auricular skin of dogs by florfenicol, terbinafine, and betamethasone acetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466046/),%,0.06,272300,DB00443,Betamethasone
,29466046,percentage absorption,"RESULTS During the 24-hour experiment, mean ± SD percentage absorption without the presence of synthetic canine cerumen was 0.28 ± 0.09% for 3H-betamethasone acetate, 0.06 ± 0.06% for florfenicol, and 0.06 ± 0.02% for 14C-terbinafine hydrochloride.","Impact of synthetic canine cerumen on in vitro penetration of auricular skin of dogs by florfenicol, terbinafine, and betamethasone acetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466046/),%,0.06,272301,DB00443,Betamethasone
